GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update